港股異動丨創業集團控股(2221.HK)復牌暴漲逾49% 擬配股總籌5000萬港元
格隆匯5月11日丨創業集團控股(2221.HK)復牌暴漲逾49%,報0.79港元,高見0.92港元創逾一年半新高,總市值5.7億港元。創業集團控股發佈公吿,2021年5月10日,公司與各認購人已訂立9份認購協議。根據認購協議,公司已有條件同意配發及發行,而認購人已有條件同意認購合共1.69472億股認購股份,認購價為0.295港元。認購價每股認購股份0.295港元較最後交易日聯交所所報的股份收市價每股0.530港元折讓約44.34%。認購事項的所得款項總額將約為5000萬港元,認購事項的所得款項淨額將約為4950萬港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.